Relmada Therapeutics Stock Investor Sentiment

RLMD Stock  USD 0.37  0.05  11.90%   
About 55% of Relmada Therapeutics' shareholders are presently thinking to get in. The analysis of overall sentiment of trading Relmada Therapeutics stock suggests that some investors are interested at this time. The current market sentiment, together with Relmada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Relmada Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Relmada Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Relmada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at news.google.com         
Relmada Therapeutics Run Up Likely Into Phase 3 Results ... - Seeking Alpha
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
Relmada Therapeutics, Inc. Short Interest Update
news
over a year ago at simplywall.st         
Is Relmada Therapeutics In A Good Position To Invest In Growth?
Simply Wall St News at Macroaxis
over a year ago at accesswire.com         
INVESTIGATION ALERT The Schall Law Firm Announces it is Investigating Claims Against Relmada Therape...
news
over a year ago at thelincolnianonline.com         
Relmada Therapeutics, Inc. Receives 19.00 Consensus PT from Brokerages
news
over a year ago at finance.yahoo.com         
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for t...
Yahoo News
over a year ago at news.google.com         
Exploring the Latest Developments in RLMD - Relmada ... - Clayton County Register
Google News at Macroaxis
over a year ago at news.google.com         
Have Effective Antidepressants Finally Arrived Developments in ... - The Journal of Clinical Psychia...
Google News at Macroaxis
over a year ago at benzinga.com         
Bragar Eagel Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encoura...
benzinga news
over a year ago at thelincolnianonline.com         
Leerink Partnrs Weighs in on Relmada Therapeutics, Inc.s Q3 2023 Earnings
news
over a year ago at insidermonkey.com         
Relmada Therapeutics, Inc. Q2 2023 Earnings Call Transcript
insidermonkey News
over a year ago at accesswire.com         
INVESTIGATION ALERT The Schall Law Firm Announces it is Investigating Claims Against Relmada Therape...
news
over a year ago at finance.yahoo.com         
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Yahoo News
over a year ago at news.google.com         
Bragar Eagel Squire, P.C. Is Investigating Shift4, Waldencast ... - The Bakersfield Californian
Google News at Macroaxis
over a year ago at accesswire.com         
INVESTOR ACTION NOTICE The Schall Law Firm Announces it is Investigating Claims Against Relmada Ther...
news
Far too much social signal, news, headlines, and media speculation about Relmada Therapeutics that are available to investors today. That information is available publicly through Relmada media outlets and privately through word of mouth or via Relmada internal channels. However, regardless of the origin, that massive amount of Relmada data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Relmada Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Relmada Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Relmada Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Relmada Therapeutics alpha.

Relmada Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of tradable shares by Ogorman Cedric of Relmada Therapeutics subject to Rule 16b-3
10/16/2024
2
Disposition of 13000 shares by Casamento Charles J of Relmada Therapeutics subject to Rule 16b-3
10/22/2024
3
Acquisition by Schmidt Eric Thomas of 57042 shares of Relmada Therapeutics subject to Rule 16b-3
10/28/2024
4
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/07/2024
5
Relmada Therapeutics, Inc. Q3 2024 Earnings Call Transcript
11/11/2024
6
Acquisition by Ence Chuck of 14500 shares of Relmada Therapeutics at 3.8657 subject to Rule 16b-3
11/20/2024
7
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
11/21/2024
8
Relmada Therapeutics Reports That Data Monitoring Committee Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unl...
12/04/2024
9
Relmada stock hits 52-week low at 0.43 amid market challenges - Investing.com
12/11/2024

Complementary Tools for Relmada Stock analysis

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
FinTech Suite
Use AI to screen and filter profitable investment opportunities